Investigational drug · Phase 3
piclidenoson
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Plaque Psoriasis, Lowe Syndrome.
Phase 3Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "piclidenoson"
First trial start
2025
Jun 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "piclidenoson", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis
- Lowe Syndrome
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "piclidenoson" as an intervention, largest first.
- A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyPivotal-lookingNot yet recruiting
Can-Fite BioPharmaIndustry
NCT06643260 · 705 participants (planned) · Start Jun 2025 · Primary completion Dec 2027
Drug: piclidenoson; Placebo · For: Plaque Psoriasis
Can-Fite BioPharmaIndustry
NCT00349466 · 80 participants · Start Jan 2007 · Primary completion May 2009
Drug: CF101; Placebo · For: Keratoconjunctivitis Sicca
Sites: Kfar Saba, Israel; Tel HaShomer, Israel; Tsrifin, Israel
Can-Fite BioPharmaIndustry
NCT01034306 · 79 participants · Start Oct 2010 · Primary completion Dec 2013
Drug: CF101; Placebo control · For: Rheumatoid Arthritis
Sites: Sofia, Bulgaria; Ashkelon, Israel · 5 sites in all
Can-Fite BioPharmaIndustry
NCT04333472 · 6 participants · Start Jan 6, 2021 · Primary completion Mar 6, 2022
Drug: Piclidenoson; Placebo · For: COVID-19; Coronavirus Infection
Sites: Sofia, Bulgaria; Jerusalem, Israel; Iași, Romania · 6 sites in all
- An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe SyndromeNot yet recruiting
Can-Fite BioPharmaIndustry
NCT07410455 · 5 participants (planned) · Start Jun 1, 2026 · Primary completion Aug 31, 2027
Drug: Piclidenoson · For: Lowe Syndrome
Sites: Roma, Italy
Newest research
PubMed records naming it or its code names, newest first.
- Triskellines A (3,6,8-Trisubstituted [1,2,4]triazolo[4,3-b]pyridazines) as Potent Antagonists of Human Adenosine Receptor A3.
Elie J, Posson F, Greverie M, et al. · J Med Chem 2026
- A3 Adenosine Receptor Agonists as Multisystem Disease Modifiers: From Molecular Signaling to Clinical Translation.
Fishman P · Biomolecules 2026
- Piclidenoson, an A3 adenosine receptor agonist, demonstrates clinical benefit in canine osteoarthritis: a pilot study.
Hanf R, Bareket-Samish A, Moulin P, et al. · Front Vet Sci 2026
- Local delivery of an adenosine receptor agonist reduces inflammation associated with contact hypersensitivity.
Bentley ER, Subick S, Doran J, et al. · Drug Deliv Transl Res 2025
- Molecular basis of ligand binding and receptor activation at the human A3 adenosine receptor.
Zhang L, Mobbs JI, Bennetts FM, et al. · Nat Commun 2025
- Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Ul Haq MZ, Ashraf S, Shaukat A, et al. · Arch Dermatol Res 2024
Also in development for Plaque Psoriasis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.